TRWP · 2 developments mapped · last assessed 2026-08-14
Market Ontology has mapped 2 macro, policy, and market developments to Traws Pharma since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Last close
Unavailable
No published quote
Market cap
Unavailable
Equity value
Diluted shares
Unavailable
Latest reported
Sector
Unavailable
Listing
Unavailable
Filings
Unavailable
No published filing
Valuation
No validated run has been published for TRWP yet, so no modelled value is shown. The TRWP valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run TRWP on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
A validated filed-statement snapshot has not been published for TRWP. Missing data is not estimated or replaced with scenario assumptions.
Current case
Open question
Traws Pharma ATM — $50M
Direct equity dilution and balance sheet strengthening. The immediate impact on share price can be negative due to increased supply, but the improved cash position can support operations and R&D.
· Moves future funding needs and associated dilution risk, probability of successful r&d outcomes due to extended cash runway, cost of equity component of wacc
What changed, by assumption
Future funding needs and associated dilution risk
2026-08-14Traws Pharma ATM — $50M
Future share count for eps calculations
2026-08-14Traws Pharma utilizes at-the-market equity program